PL3829563T3 - Kwas 3-sulfopropanowy do leczenia zaburzeń neurodegeneracyjnych - Google Patents

Kwas 3-sulfopropanowy do leczenia zaburzeń neurodegeneracyjnych

Info

Publication number
PL3829563T3
PL3829563T3 PL19752795.5T PL19752795T PL3829563T3 PL 3829563 T3 PL3829563 T3 PL 3829563T3 PL 19752795 T PL19752795 T PL 19752795T PL 3829563 T3 PL3829563 T3 PL 3829563T3
Authority
PL
Poland
Prior art keywords
neurodegenerative disorders
treating neurodegenerative
sulfopropanoic acid
sulfopropanoic
acid
Prior art date
Application number
PL19752795.5T
Other languages
English (en)
Inventor
John Hey
Petr Kocis
Martin TOLAR
Neil William FLANZRAICH
Original Assignee
Alzheon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheon, Inc. filed Critical Alzheon, Inc.
Publication of PL3829563T3 publication Critical patent/PL3829563T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PL19752795.5T 2018-08-01 2019-07-30 Kwas 3-sulfopropanowy do leczenia zaburzeń neurodegeneracyjnych PL3829563T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862713061P 2018-08-01 2018-08-01
PCT/US2019/044023 WO2020028290A1 (en) 2018-08-01 2019-07-30 Methods for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
PL3829563T3 true PL3829563T3 (pl) 2025-04-07

Family

ID=67614642

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19752795.5T PL3829563T3 (pl) 2018-08-01 2019-07-30 Kwas 3-sulfopropanowy do leczenia zaburzeń neurodegeneracyjnych

Country Status (27)

Country Link
US (2) US12083082B2 (pl)
EP (1) EP3829563B1 (pl)
JP (1) JP7573512B2 (pl)
KR (1) KR102716959B1 (pl)
CN (1) CN112867485A (pl)
AU (1) AU2019315853B2 (pl)
BR (1) BR112021001739A2 (pl)
CL (1) CL2021000269A1 (pl)
DK (1) DK3829563T3 (pl)
EA (1) EA202190406A1 (pl)
ES (1) ES3011716T3 (pl)
FI (1) FI3829563T3 (pl)
HR (1) HRP20250206T1 (pl)
HU (1) HUE070101T2 (pl)
IL (1) IL280424B2 (pl)
LT (1) LT3829563T (pl)
MX (1) MX2021001287A (pl)
MY (1) MY206530A (pl)
PH (1) PH12021550213A1 (pl)
PL (1) PL3829563T3 (pl)
PT (1) PT3829563T (pl)
RS (1) RS66516B1 (pl)
SG (1) SG11202100767XA (pl)
SI (1) SI3829563T1 (pl)
SM (1) SMT202500080T1 (pl)
UA (1) UA130011C2 (pl)
WO (1) WO2020028290A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3829563T3 (en) * 2018-08-01 2025-02-24 Alzheon Inc 3-sulfopropanoic acid for treating neurodegenerative disorders
JP2022536803A (ja) * 2019-06-17 2022-08-18 アルツェオン・インコーポレーテッド 神経変性障害を治療する方法
IL313404A (en) * 2021-12-09 2024-08-01 Alzheon Inc ALZ-801 for use in the treatment of Alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
KR101608445B1 (ko) 2006-10-12 2016-04-01 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
EP2852388A4 (en) 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US20150359849A1 (en) 2013-01-31 2015-12-17 President And Fellows Of Harvard College Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition
WO2015143447A2 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
PT3347002T (pt) 2015-09-10 2023-07-27 Alzheon Inc Tratamento de doença de alzheimer numa população particular de pacientes
DK3829563T3 (en) * 2018-08-01 2025-02-24 Alzheon Inc 3-sulfopropanoic acid for treating neurodegenerative disorders

Also Published As

Publication number Publication date
IL280424B1 (en) 2024-09-01
CN112867485A (zh) 2021-05-28
CA3108150A1 (en) 2020-02-06
PT3829563T (pt) 2025-02-18
HRP20250206T1 (hr) 2025-04-11
WO2020028290A1 (en) 2020-02-06
US20210315847A1 (en) 2021-10-14
ES3011716T3 (en) 2025-04-08
IL280424A (en) 2021-03-01
EP3829563A1 (en) 2021-06-09
MX2021001287A (es) 2021-07-15
US12083082B2 (en) 2024-09-10
UA130011C2 (uk) 2025-10-15
SI3829563T1 (sl) 2025-05-30
SMT202500080T1 (it) 2025-03-12
SG11202100767XA (en) 2021-02-25
KR102716959B1 (ko) 2024-10-11
RS66516B1 (sr) 2025-03-31
CL2021000269A1 (es) 2021-06-18
JP2021533128A (ja) 2021-12-02
MY206530A (en) 2024-12-19
DK3829563T3 (en) 2025-02-24
KR20210039415A (ko) 2021-04-09
LT3829563T (lt) 2025-02-25
EA202190406A1 (ru) 2021-10-15
EP3829563B1 (en) 2024-11-20
PH12021550213A1 (en) 2021-11-03
FI3829563T3 (fi) 2025-02-17
AU2019315853A1 (en) 2021-03-18
HUE070101T2 (hu) 2025-05-28
JP7573512B2 (ja) 2024-10-25
US20250213507A1 (en) 2025-07-03
BR112021001739A2 (pt) 2021-04-27
IL280424B2 (en) 2025-01-01
AU2019315853B2 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
IL256380A (en) Vesicular monoamine transporter 2 inhibitors for the treatment of neurological diseases or disorders
IL262222A (en) Anti-aging antibodies for the treatment of neurodegenerative disorders
SMT201900172T1 (it) Ammino triazoli sostituiti utili come inibitori della chitinasi umana
IL281052A (en) Treatment of liver disorders
PT4088720T (pt) Rimegepant para distúrbios relacionados com o cgrp
HUE056356T2 (hu) Tetrahidro-8H-pirido[1,2-a]pirazin-8-on vegyületek, mint COMT inhibitorok neurodegeneratív rendellenességek kezelésére
GB201803010D0 (en) Neurodegenerative disorders
ZA201800831B (en) Compositions and methods for treating and preventing neurodegenerative disorders
ZA201907238B (en) Compositions for treating neurodegenerative diseases
IL280424A (en) Methods for treating neurodegenerative disorders
SG11202007286TA (en) Methods for treating mitochondrial disorders
DK4296670T3 (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
EP3313387A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
GB201701404D0 (en) Therapies for treating inflammatory disorders
GB201701455D0 (en) Neurodegenerative disorders
IL289018A (en) Methods for treating neurodegenerative disorders
HK40072836A (en) Methods for treating neurodegenerative disorders
HK40069546A (en) Methods for treating neurodegenerative disorders
HK40019969A (en) Methods for treating neurodegenerative disorders
HK40017730A (en) Methods for treating mitochondrial disorders
PT3420084T (pt) Nova abordagem para tratamento de disfunções inflamatórias